Status:

COMPLETED

Fine Particle pMDI Formoterol/Beclomethasone in Asthmatics With and Without Spacer: Comparative Efficacy Evaluation

Lead Sponsor:

Universidade Federal de Pernambuco

Collaborating Sponsors:

Universidade Federal do vale do São Francisco

Conditions:

Asthma

Eligibility:

All Genders

18-65 years

Phase:

PHASE3

Brief Summary

Adequate pharmacological treatment controls symptoms in most asthmatics. Pressurized metered dose inhalers (pMDI)are the most used drug delivery devices. Valved holding chambers of different types and...

Detailed Description

This is a randomized, parallel controlled study with blind outcome evaluation to compare the efficacy of the fine particle combination Beclomethasone/Formoterol administered with or without valved hol...

Eligibility Criteria

Inclusion

  • Adult, age 18 to 65 years, both sexes;
  • Clinical diagnosis of moderate to severe persistent asthma;
  • Nonsmoker;
  • Agree to participate and sign the Informed Consent;
  • ACT Score \<= 19
  • FEV1 \<= 80% of predicted;
  • History of response to FEV1 greater than 10%;
  • Patients who are already using Inhaled steroids at medium to high doses (Beclomethasone, budesonide, fluticasone) with longa-acting beta2 agonists (formoterol or salmeterol)
  • Proper use of metered-dose inhaler (after orientation)

Exclusion

  • Patient diagnosed with Chronic Obstructive Pulmonary Disease (COPD);
  • Current smokers or have stopped for less than 10 years;
  • Patients with a history of recent near-fatal asthma (less than 12 months);
  • Patients with a history of recent asthma hospitalization (last 6 months);
  • Patients with airway infection symptoms for less than 4 weeks;
  • Participation in any experimental study up to 1 (one) year from selection visit;
  • Hospitalization for any reason up to 8 weeks before selection visit;
  • History of liver, cardiac, renal, pulmonary or gastrointestinal diseases, epileptic, psychiatric or hematologic disorders, uncontrolled hypertension, rheumatology/orthopedic disorders that interferes with pMDI use;
  • Patients unable to properly use the pMDI during the selection

Key Trial Info

Start Date :

April 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2013

Estimated Enrollment :

45 Patients enrolled

Trial Details

Trial ID

NCT01453881

Start Date

April 1 2011

End Date

June 1 2013

Last Update

March 31 2015

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hospital das Clínicas - Universidade Federal de Pernambuco

Recife, Pernambuco, Brazil, 50740-520